YAP1 Antibodies

Structure of YAP1

YAP1 is a relatively large transcriptional regulatory protein, and its molecular weight varies among different subtypes and post-translational modifications, typically ranging from 65 to 75 kDa. This difference mainly stems from its complex domain and variable phosphorylation state.

The YAP1 protein contains approximately 450 to 500 amino acids and interacts with multiple partners through its complex domain. The key to the protein structure is a WW domain, which acts like a molecular key, specifically recognizing and binding to transcription factors containing specific proline motifs (PPxY), such as the TEAD family. The activity of YAP1 is mainly regulated by phosphorylation: when the Hippo pathway is activated, upstream kinases (LATS1/2) phosphorylate multiple serine sites of YAP1 (such as S127), causing it to be retained in the cytoplasm and become inactive. Conversely, in the activated state, YAP1 enters the cell nucleus and combines with factors such as TEAD, jointly initiating the gene program that promotes cell proliferation and growth.

Fig. 1 YAP1 Dysfunction: Driving Diabetic Kidney Disease Progression.¹

Key structural properties of YAP1:

• Contains multiple functional domains (WW, TEAD-binding domain, etc.)
• Disordered regions exist that mediate phase separation and transcriptional condensates formation
• Phosphorylation switches regulate its nucleoplasmic shuttle (key site Ser127)
• Mechanically sensitive modules sense cellular tension and microenvironmental signals

Functions of YAP1

The core function of YAP1 is to regulate gene expression as a transcriptional co-activator. However, its functions vary depending on the cellular environment and play different roles in development, cancer, and tissue regeneration.

The activity of YAP1 is mainly regulated by its intracellular localization: after phosphorylation, it remains in the cytoplasm and is in a "closed" state; after dephosphorylation, it enters the nucleus and is in an "open" state. This unique "spatial regulation" mechanism enables it to efficiently integrate multiple upstream signals

Applications of YAP1 and YAP1 Antibody in Literature

1. Ye, Siyang, et al. "YAP1 preserves tubular mitochondrial quality control to mitigate diabetic kidney disease." Redox Biology 78 (2024): 103435. https://doi.org/10.1016/j.redox.2024.103435

The article indicates that in diabetic nephropathy, the inactivation of YAP1 in renal tubular cells leads to the loss of control over mitochondrial quality regulation, causing abnormal mitochondrial function, and promotes the polarization of M1 in macrophages by secreting CXCL1, accelerating disease progression. Activation of YAP1 can improve mitochondrial function and alleviate kidney damage.

2. Sadhukhan, Pritam, et al. "YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation." The Journal of Clinical Investigation 135.2 (2025). https://doi.org/10.1172/JCI171164

The article indicates that in bladder cancer, YAP1 shapes the immunosuppressive microenvironment by activating the IL-6/STAT3 pathway and regulating chemokines, thereby promoting the characteristics of tumor stem cells. Inhibiting YAP1 can reduce immunosuppressive cells such as M2 macrophages and, when used in combination with immune checkpoint inhibitors, has potential therapeutic value.

3. Li, Huiying, et al. "Mir-484 contributes to diminished ovarian reserve by regulating granulosa cell function via YAP1-mediated mitochondrial function and apoptosis." International journal of biological sciences 18.3 (2022): 1008. https://doi.org/10.7150/ijbs.68028

The article indicates that in diminished ovarian function (DOR), the expression of miR-484 in granulosa cells is upregulated. It directly targets and inhibits YAP1, inducing mitochondrial dysfunction, thereby reducing cell proliferation, promoting cell apoptosis, and ultimately leading to a decline in ovarian reserve function. Replenishing YAP1 can reverse this damage.

4. Li, Yuexian, et al. "ITGB1 enhances the radioresistance of human non-small cell lung cancer cells by modulating the DNA damage response and YAP1-induced epithelial-mesenchymal transition." International journal of biological sciences 17.2 (2021): 635. https://doi.org/10.7150/ijbs.52319

The article indicates that in non-small cell lung cancer, integrin ITGB1 enhances the radioresistance of cancer cells by promoting the expression and nuclear translocation of YAP1 and inducing epithelial-mesenchymal transition (EMT). Targeting ITGB1 can inhibit YAP1 and enhance radiotherapy sensitivity.

5. Calvet, Loreley, et al. "YAP1 is essential for malignant mesothelioma tumor maintenance." Bmc Cancer 22.1 (2022): 639. https://doi.org/10.1186/s12885-022-09686-y

The article indicates that in malignant pleural mesotheliomas with abnormal Hippo signaling pathways, the continuous activation of YAP1 is the key to maintaining tumor growth. Inhibiting YAP1 can block the transcription of YAP1/TEAD, induce apoptosis of cancer cells and lead to the regression of already formed tumors, which provides a basis for targeting the YAP1-TEAD complex to treat this cancer.

Creative Biolabs: YAP1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality YAP1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom YAP1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our YAP1 antibodies, custom preparations, or technical support, contact us at email.